These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Tennezé L; Tarral E; Ducloux N; Funck-Brentano C Clin Pharmacol Ther; 2002 Aug; 72(2):112-22. PubMed ID: 12189358 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation. Verrier RL; Belardinelli L J Cardiovasc Pharmacol; 2020 Apr; 75(4):276-283. PubMed ID: 32032206 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic equivalence of two flecainide acetate formulations in patients with paroxysmal atrial fibrillation by QRS analysis of ambulatory electrocardiogram. Coumel P; Maison-Blanche P; Tarral E; Périer A; Milliez P; Leenhardt A J Cardiovasc Pharmacol; 2003 May; 41(5):771-9. PubMed ID: 12717109 [TBL] [Abstract][Full Text] [Related]
12. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. Ohmura H; Nukada T; Mizuno Y; Yamaya Y; Nakayama T; Amada A J Vet Med Sci; 2000 Jul; 62(7):711-5. PubMed ID: 10945288 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs. Sällström J; Al-Saffar A; Pehrson R J Pharmacol Toxicol Methods; 2014; 69(1):24-9. PubMed ID: 24140388 [TBL] [Abstract][Full Text] [Related]
14. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects. Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235 [TBL] [Abstract][Full Text] [Related]
15. Impact of serum flecainide level on control of atrial fibrillation in a case treated with cardiac resynchronization therapy. Doki K; Homma M; Kuga K; Kawano S; Aonuma K; Yamaguchi I; Kohda Y J Clin Pharm Ther; 2007 Aug; 32(4):409-11. PubMed ID: 17635343 [TBL] [Abstract][Full Text] [Related]
16. ST-segment elevation in a patient receiving flecainide. Chung-Esaki H; Tabas J; Goldschlager N Arch Intern Med; 2011 Jan; 171(1):11-3. PubMed ID: 21220653 [No Abstract] [Full Text] [Related]
17. Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects. Boriani G; Capucci A; Strocchi E; Calliva R; Santarelli A; Biffi M; Magnani B Int J Clin Pharmacol Res; 1993; 13(4):211-9. PubMed ID: 8150547 [TBL] [Abstract][Full Text] [Related]
18. Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease. Wang JA; Lau CP; Tai YT; Wu BZ Clin Cardiol; 1995 Mar; 18(3):140-4. PubMed ID: 7743684 [TBL] [Abstract][Full Text] [Related]
19. Ablation of a left-sided accessory pathway during atrial fibrillation facilitated by intravenous flecainide. Ng GA; Rankin AC J Interv Card Electrophysiol; 1999 Oct; 3(3):279-82. PubMed ID: 10490486 [No Abstract] [Full Text] [Related]
20. Therapeutic monitoring of class I antiarrhythmic agents using high-resolution electrocardiography instead of blood samples. Sutovsky I; Katoh T; Takayama H; Ono T; Takano T Circ J; 2003 Mar; 67(3):195-8. PubMed ID: 12604865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]